A study by Jiefei Han et al. sequenced the complementarity-determining region 3 of the TCRβ chains isolated from PD-1+ CD8+ T cells to investigate its value in predicting response to anti-PD-1/PD-L1 therapy in NSCLC patients. This evidence concerns the gene CD8A and non-small cell lung carcinoma.